• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 144/A filed by Mereo BioPharma Group plc

    6/24/24 7:04:05 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MREO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144/A

    144/A: Filer Information

    Filer CIK
    0001297000
    Filer CCC
    XXXXXXXX
    Previous Accession Number Of The Filing
    0000950170-24-075619
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144/A: Issuer Information

    Name of Issuer
    Mereo BioPharma Group plc
    SEC File Number
    001-38452
    Address of Issuer
    4th Floor, One Cavendish Place
    London
    UNITED KINGDOM
    W1G 0QF
    Phone
    44-333 023 7300
    Name of Person for Whose Account the Securities are To Be Sold
    Scots-Knight Denise
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144/A: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    American Depositary Shares Representing Ordinary Shares
    Morgan Stanley & Co. LLC
    1585 Broadway
    New York � NY � 10036-8293
    146284582210.3276515025406/25/2024
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144/A: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    American Depositary Shares Representing Ordinary Shares06/21/2024Same Day Cashless Exercise and SaleIssuerCheckbox not checked28209006/21/2024Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144/A: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144/A: Remarks and Signature

    Remarks
    This form 144 amends and supersedes the form 144 filed on June 20, 2024. The name and address of the broker has been corrected.
    Date of Notice
    06/24/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Denise Scots-Knight

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MREO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MREO

    DatePrice TargetRatingAnalyst
    12/30/2025$0.50Buy → Hold
    Jefferies
    3/27/2025$7.00Overweight
    Analyst
    12/6/2024$7.00Buy
    Jefferies
    6/13/2024$8.00Outperform
    Robert W. Baird
    10/13/2023$4.00Buy
    BTIG Research
    8/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MREO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Hughes-Wilson Alexandra

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/2/26 4:30:08 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by General Counsel Sermon Charles

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/2/26 4:30:07 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fox Christine Ann

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/2/26 4:30:04 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MREO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mereo BioPharma downgraded by Jefferies with a new price target

    Jefferies downgraded Mereo BioPharma from Buy to Hold and set a new price target of $0.50

    12/30/25 7:20:11 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Mereo BioPharma with a new price target

    Analyst initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $7.00

    3/27/25 8:18:53 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Mereo BioPharma with a new price target

    Jefferies initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $7.00

    12/6/24 7:56:53 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MREO
    SEC Filings

    View All

    SEC Form S-8 filed by Mereo BioPharma Group plc

    S-8 - Mereo BioPharma Group plc (0001719714) (Filer)

    2/2/26 4:01:55 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Group plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Mereo BioPharma Group plc (0001719714) (Filer)

    1/12/26 8:09:57 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Mereo BioPharma Group plc

    SCHEDULE 13G - Mereo BioPharma Group plc (0001719714) (Subject)

    1/9/26 5:24:27 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MREO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mereo BioPharma Provides Corporate Update

    Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program  Cash balance of approximately $41 million as of December 31, 2025; runway guidance updated to mid-2027 LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its programs, setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, which is being studied for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), and revi

    1/12/26 8:00:00 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

    Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improvements in bone mineral density with strong statistical significance LONDON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical stage biopharmaceutical company focused on rare diseases, today announced results from the Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). Neither study achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate

    12/29/25 8:31:00 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights

    Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027  LONDON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided recent corporate highlights.  "We are rapidly approaching a major transition period in our corporate evolution, with the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on track to

    11/10/25 4:01:00 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MREO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 4:18:45 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 3:30:42 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 11:44:32 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MREO
    Leadership Updates

    Live Leadership Updates

    View All

    Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

    LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e

    5/17/22 8:00:00 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

    LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C

    3/1/22 8:00:00 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

    LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off

    9/20/21 8:00:00 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MREO
    Financials

    Live finance-specific insights

    View All

    Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights

    Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027  LONDON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided recent corporate highlights.  "We are rapidly approaching a major transition period in our corporate evolution, with the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on track to

    11/10/25 4:01:00 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

    Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027  LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided recent corporate highlights.  "We look forward to the final analysis for the two ongoing Phase 3 studies for setrusumab in osteogenesis imperfecta, the Phase 3 Orbit study in pediatric and young adult patients, and the Pha

    8/12/25 7:35:56 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

    Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

    5/13/25 7:30:05 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care